Cell Therapy
Gene Editing
Scaling Up
Viral/Non-Viral Vectors

Case Study: Process Development and Large-Scale GMP Production for Lentiviral Vectors

Phacilitate
11 June 2020
SHARE NOW

Vibrant communities and market intelligence.

How efficient are your lentiviral vector large-scale production and purification processes?

MolMed offers in-house proprietary processes for lentiviral (LV) vector production at large scale. As the evolution of the well-established GMP 48L CF process MolMed is developing a robust and scalable process for the industrial-scale production of both LV vectors for use in gene-modified cell therapy using a scalable platform that includes the iCELLis bioreactor vector production and a downstream purification platform that includes chromatography and TFF steps.

In this session, you are presented with a wealth of productivity and quality data obtained with the CF process and the development and optimisation of the LV production process in a bioreactor.

During this webinar, you will learn:

  • How to perform an efficient LV vector large-scale production and purification processes
  • Process development and large-scale production process using the iCELLis platform
  • How to design an industrial scale viral vector production from bulk production to final filled product